Fig. 9
From: A prognostic model based on necroptosis-related genes for prognosis and therapy in bladder cancer
Correlation between the prognostic model and somatic mutation and drug sensitivity. A, B Waterfall plots of 20 genes with the highest mutation rate in the high-risk group (A) and low-risk group (B). Kaplan–Meier analysis of TMB in BLCA patients based on TMB defined groups (C) and risk score with TMB-defined groups (D). E Correlation between expression of ICGs and risk score. F TIDE score. Correlation between the Prognostic model and IC50 values of chemotherapy and immunotherapy drugs, including doxorubicin (G), docetaxel (H), cisplatin (I), tipifarnib (J), sunitinib (K), sorafenib (L) and pazopanib (M)